Roche announced that it has acquired the CE mark for Elecsys Dengue Ag, their high-throughput, fully-automated immunoassay system that helps the diagnosis of acute dengue virus infections.
Reflecting strong operational performance and consistent market momentum, Cipla Limited has reported a rise in both revenue and profitability for the quarter and half year ended September 30, 2025. The company’s results highlight continued growth in
Eli Lilly's Omvoh (mirikizumab) shows early and lasting relief in bowel urgency for patients with ulcerative colitis, reducing severity and frequency by over 50 percent in the Phase 3b LUCENT URGE study.
Helex, a therapeutics startup operating across the US and India, has secured an oversubscribed $3.5 million Seed round led by pi Ventures, with participation from Bluehill Capital, SOSV, and a network of global investors. This latest investment bring
Autoimmune diseases represent a significant and growing global health issue, affecting approximately 10% of the population and imposing a considerable burden on both patients and healthcare systems. Despite progress in therapeutic innovations, there
The US Food and Drug Administration (FDA) has tentatively approved Amneal Pharmaceuticals Inc.'s Abbreviated New Drug Application (ANDA) for beclomethasone dipropionate HFA inhalation aerosol (40 mcg/actuation and 80 mcg/actuation), according to the
Health Biotech Limited, an Indian pharma company focused on research, participated successfully at CPHI Frankfurt 2025, a leading global pharmaceutical exhibition, held from October 28 to 30 in Germany.
FUJIFILM India has recently introduced its new healthcare technology, FW 500 Clinical Chemistry Analyzer, which consolidates In-vitro Diagnostics. The FW500 offers both the expertise in dry chemistry Fujifilm has developed over 40 years plus...
Dr. Reddy's Laboratories (DRL) will probably take some time to release its generic injectable semaglutide in Canada after receiving the health regulatory body, Health Canada's Pharmaceutical Drugs Directorate, Notice of Non-Compliance (NoN).
Piramal Pharma Solutions, a global contract development and manufacturing organization (CDMO) under Piramal Pharma Ltd., has signed a Memorandum of Understanding (MOU) with Korean biotech company IntoCell Inc...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")